 |
 |
 |
 |
 |
 |
Treatment Name: |
 |
NTI 0501: An Open-Labeled, Extended-Use of Human Corticotropin-Releasing Factor (hCRF) (Xerecept) Intended for Patients Who Participate in Dexamethasone-Sparing Studies NTI 0302 or NTI 0303 |
 |
 |
 |
 |
Phase: |
 |
Phase 3 |
 |
 |
 |
 |
 |
 |
Treatment ID#: |
 |
1665 NTI 0501 |
 |
 |
 |
 |
Age Group: |
 |
Adults Only |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
50: Requires considerable assistance and frequent medical care |
 |
 |
 |
 |
Conditions: |
 |
Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed |
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
03/01/2008 |
 |
 |
 |
 |
Tumor Types: |
 |
Anaplastic Astrocytoma Any Malignant Brain Tumor Brainstem Glioma Germ Cell Tumors Gliosarcoma Metastatic Brain Tumor Oligodendroglioma High Grade |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
The purpose of this study is to examine the long-term safety and tolerability of human corticotropin-releasing factor (hCRF), XERECEPT®, in patients requiring dexamethasone (Decadron®) to treat peritumoral brain edema. This open-label, extended-use study is open to all patients who participate in either of the blinded studies, NTI 0302 or NTI 0303, including patients who may have discontinued blinded study medication early but completed the protocol-stipulated follow-up periods. |
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Less-Toxics |
 |
 |
 |
 |
Contact: |
 |
Jeffrey Raizer MD Director, Medical Neuro-oncology Northwestern University, The Robert H. Lurie Comprehensive Cancer Center Contact: Lilia Gallot, MD, CCRC Chicago, IL 60611 USA Phone: 312-695-1363 Fax: E-mail: jraizer@nmff.org Website: |
 |
 |
- Last updated refers to the date when our listing for each treatment was last updated.
- ID is a combination of our internal ID and the official ID for the trial, if any.
- Min Karnofsky is a general guide to how well you have to function to use this treatment
|
|